Walleye Capital’s 10x Genomics TXG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-1,577
Closed -$25.7K 5005
2025
Q4
$25.7K Buy
+1,577
New +$23.8K ﹤0.01% 4214
2025
Q2
Sell
-266,331
Closed -$2.33M 5055
2025
Q1
$2.33M Sell
266,331
-25,554
-9% -$322K 0.01% 1307
2024
Q4
$4.19M Buy
291,885
+281,975
+2,845% +$4.45M 0.01% 1201
2024
Q3
$224K Sell
9,910
-2,848
-22% -$58.9K ﹤0.01% 3924
2024
Q2
$248K Buy
12,758
+6,119
+92% +$160K ﹤0.01% 4138
2024
Q1
$249K Buy
+6,639
New +$292K ﹤0.01% 3817
2023
Q4
Sell
-17,220
Closed -$749K 5542
2023
Q3
$710K Buy
17,220
+15,873
+1,178% +$826K ﹤0.01% 2530
2023
Q2
$75.2K Buy
+1,347
New +$72.9K ﹤0.01% 3515
2021
Q3
Sell
-3,516
Closed -$689 1817
2021
Q2
$689 Sell
3,516
-1,202
-25% -$218K 0.02% 622
2021
Q1
$854 Sell
4,718
-6,396
-58% -$1.1M 0.05% 362
2020
Q4
$1.57K Buy
11,114
+2,230
+25% +$324K 0.11% 165
2020
Q3
$1.11M Buy
8,884
+6,461
+267% +$678K 0.12% 222
2020
Q2
$216K Buy
+2,423
New +$189K 0.05% 412

Other funds holding TXG

Walleye Capital's TXG Position: Q1 2026 in Review

Walleye Capital sold out of 10x Genomics (TXG) in Q1 2026, closing a stake of 1,577 shares — an estimated $25.7K sold.

Walleye Capital first reported a position in TXG in Q2 2020 and held it in 13 quarters. The position peaked at $4.19M in Q4 2024. 329 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

  • Walleye Capital reported no remaining 10x Genomics position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 1,577 10x Genomics shares in Q1 2026, an estimated $25.7K.
  • Walleye Capital first reported a position in 10x Genomics in Q2 2020 and held it in 13 quarters.
  • Walleye Capital's 10x Genomics position peaked at $4.19M in Q4 2024.
  • 329 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.